Comparative Pharmacology
Head-to-head clinical analysis: CARMOL HC versus CORTALONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARMOL HC versus CORTALONE.
CARMOL HC vs CORTALONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carmol HC is a combination of urea (a keratolytic) and hydrocortisone (a corticosteroid). Urea softens and dissolves the intercellular matrix of the stratum corneum, promoting desquamation and enhancing penetration of hydrocortisone. Hydrocortisone suppresses inflammation by induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response, and regulate metabolism.
Apply a thin film to affected area twice daily; topical, not for ophthalmic or oral use.
10-40 mg orally once daily in the morning; for acute exacerbations, up to 60 mg/day divided into 2-4 doses.
None Documented
None Documented
1-2 hours (hydrocortisone acetate); clinical effects persist longer due to local anti-inflammatory action; tissue half-life not well defined.
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion of metabolites (40-60%) as glucuronide and sulfate conjugates; <10% unchanged; biliary/fecal elimination accounts for <20%.
Primarily renal (60-70% as unchanged drug), with 10-20% biliary/fecal.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid